Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

800 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy of praziquantel versus As+SMP (Co-Arinate FDC ®) in the treatment of Schistosoma haematobium in 6-15 year old Malian children. The nul-hypothesis in this study is that the combination of As+SMP is more effective than praziquantel in the treatment of S. haematobium infected children.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection

NCT04264130

Schistosomiasis Haematobia

COMPLETED PHASE2

Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children

NCT03893097

Schistosoma Haematobium Schistosoma Mansoni

COMPLETED PHASE3

Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana

NCT01459146

Malaria Schistosomiasis Helminthiasis +2 more

UNKNOWN PHASE4

Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria

NCT00484900

Plasmodium Falciparum Malaria

COMPLETED PHASE3

Severe Malaria in Remote Areas- Closing the Evidence Gap

NCT06806956

Severe Malaria

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schistosoma Haematobium

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Artesunate+Sulfamethoxypyrazine/pyrimethamin

Intervention Type DRUG

Praziquantel

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Co-Arinate FDC ®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 6-15 years
* In good health, according to study doctor
* Suffering from urinary schistosomiasis, as diagnosed by the presence of S. haematobium eggs in the urine.
* Residents of Djalakorodji
* Capable of taking oral medication
* Written informed consent to participate in the study, obtained from parent or legal guardian.

Exclusion Criteria

* Weighing more than 50 kg
* Being pregnant or lactating at the time of the study
* Patient has a severe concomitant disease, as determined by the clinical examination, such as cerebral cysticercosis, HIV,...
* Signs of severe malnutrition (children weighing/measuring more than 3 standard deviations or less than 70% of the median standard reference values determined by WHO, or with systemic oedema affecting both feet).
* Hypersensitivity to As, SMP or PZQ
* Having taken other antimalarial or antischistosomal medication during the study.
* Having participated in previous similar studies

Minimum Eligible Age

6 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No